A validated PBPK model is used in lieu of clinical studies to assess the risk of CYP3A4-mediated DDIs for an anticancer drug rivoceranib (victim) with weak/moderate CYP3A4 inhibitors (ranitidine/fluconazole), or with a moderate CYP3A4 inducer (efavirenz)

Conference: ASCPT


A PBPK model for anticancer drug rivoceranib (RIV), a tyrosine kinase inhibitor (TKI) that selectively targets vascular endothelia growth factor receptor-2 ((VEGFR-2)  was developed and validated to assess potential risk of CYP3A4-mediated DDIs.

By Jasmina Novakovica, Grace Fraczkiewicza, Seong H Jangb, Jeff Heckmanb, Bill Stricklandb, Mingyan Zhouc, and Nassim Djeblid

ASCPT 2023 Annual Meeting, March 24, 2023, Atlanta, GA

Download Slides